RT Journal
A1 Monson T
T1 HIv and liver disease
JF JAMA
JO JAMA
YR 2012
FD July 25
VO 308
IS 4
SP 410
OP 411
DO 10.1001/jama.308.4.410-b
UL http://dx.doi.org/10.1001/jama.308.4.410-b
AB 
Chapter 1 sketches current trends of the HIV epidemic, although the most recent data are from 2010. In the chapter on liver disease in HIV, Butt addresses well-recognized factors of drug-related liver injury: ethanol use and coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV). It is generally less appreciated that nonalcoholic fatty liver disease is relatively common, with magnetic resonance imaging and computed tomography studies reporting a 37% to 42% rate of steatosis among patients with HIV alone, increasing to 67% to 69% among those coinfected with HBV or HCV (pp 10-11). The degree of steatosis correlates with the risk of fibrosis. A special notation is also made of “nodular regenerative hyperplasia,” a newer entity perhaps 3 times more common in patients with vs without HIV.